Tweet
Antimicrob Agents Chemother. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid, against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents
[Source: Antimicrobial Agents and Chemotherapy, full page: (LINK). Abstract, edited.]
-------
Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid, against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents
Jillian L. Descourouez 2, Margaret R. Jorgenson 2, Justine E. Wergin 1 and Warren E. Rose 1,2
Author Affiliations: <SUP>1</SUP>Pharmacy Practice Division, University of Wisconsin School of Pharmacy, Madison USA; <SUP>2</SUP>Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, USA
ABSTRACT
Fosfomycin is a potential option for VRE infections despite limited in vitro and clinical data. In this study, thirty-two VRE from renal transplant patients with urinary stent infections were susceptible to fosfomycin, daptomycin, linezolid, and resistant to amoxicillin, minocycline, and nitrofurantoin based on MIC<SUB>50/90</SUB>. Fosfomycin was bacteriostatic at 0.5-16 x MIC (32-2048 μg/ml); synergy occurred when combined with daptomycin (2.8-3.9 log<SUB>10</SUB> cfu/ml kill; p<0.001) or amoxicillin (2.6-3.4; p<0.05). These combinations may be potent options to treat VRE urinary infections pending investigation of clinical efficacy.
FOOTNOTES
Address correspondence to: Warren E. Rose, Pharm.D., 777 Highland Avenue, Rennebohm Hall 4123, Madison, WI 53705, Tel: 608.890.1917, Fax: 608.265.5421, email: werose@pharmacy.wisc.edu
Copyright ? 2012, American Society for Microbiology. All Rights Reserved.
-Jillian L. Descourouez 2, Margaret R. Jorgenson 2, Justine E. Wergin 1 and Warren E. Rose 1,2
Author Affiliations: <SUP>1</SUP>Pharmacy Practice Division, University of Wisconsin School of Pharmacy, Madison USA; <SUP>2</SUP>Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, USA
ABSTRACT
Fosfomycin is a potential option for VRE infections despite limited in vitro and clinical data. In this study, thirty-two VRE from renal transplant patients with urinary stent infections were susceptible to fosfomycin, daptomycin, linezolid, and resistant to amoxicillin, minocycline, and nitrofurantoin based on MIC<SUB>50/90</SUB>. Fosfomycin was bacteriostatic at 0.5-16 x MIC (32-2048 μg/ml); synergy occurred when combined with daptomycin (2.8-3.9 log<SUB>10</SUB> cfu/ml kill; p<0.001) or amoxicillin (2.6-3.4; p<0.05). These combinations may be potent options to treat VRE urinary infections pending investigation of clinical efficacy.
FOOTNOTES
Address correspondence to: Warren E. Rose, Pharm.D., 777 Highland Avenue, Rennebohm Hall 4123, Madison, WI 53705, Tel: 608.890.1917, Fax: 608.265.5421, email: werose@pharmacy.wisc.edu
Copyright ? 2012, American Society for Microbiology. All Rights Reserved.
-------